S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
NASDAQ:NEO

NeoGenomics (NEO) Stock Price, News & Analysis

$13.53
-0.24 (-1.74%)
(As of 04/19/2024 ET)
Today's Range
$13.42
$13.79
50-Day Range
$13.53
$16.79
52-Week Range
$11.03
$21.22
Volume
771,592 shs
Average Volume
625,665 shs
Market Capitalization
$1.73 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.50

NeoGenomics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
44.1% Upside
$19.50 Price Target
Short Interest
Bearish
5.67% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.57mentions of NeoGenomics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$38,702 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.20) to ($0.10) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.98 out of 5 stars

Medical Sector

573rd out of 909 stocks

Testing Laboratories Industry

1st out of 1 stocks

NEO stock logo

About NeoGenomics Stock (NASDAQ:NEO)

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

NEO Stock Price History

NEO Stock News Headlines

NeoGenomics Announces Senior Leadership Promotions
Double your money before lunch?
Unlike bacterial infections, viral infections can be difficult to treat with medicine. Usually, if you've got a virus, your doctor's best advice is to simply rest and allow your immune system to fight back. Antiviral medications prevent viruses from reproducing, but they can't actually stop the virus. However, scientists may have just found a new way to fight back.
Double your money before lunch?
Unlike bacterial infections, viral infections can be difficult to treat with medicine. Usually, if you've got a virus, your doctor's best advice is to simply rest and allow your immune system to fight back. Antiviral medications prevent viruses from reproducing, but they can't actually stop the virus. However, scientists may have just found a new way to fight back.
NeoGenomics Inc.
NEO Mar 2024 10.000 put
Evaluating NeoGenomics: Insights From 4 Financial Analysts
Q4 2023 Neogenomics Inc Earnings Call
NeoGenomics (NEO) Q4 Earnings and Revenues Beat Estimates
Recap: NeoGenomics Q4 Earnings
NeoGenomics: Q4 Earnings Snapshot
See More Headlines
Receive NEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/20/2024
Today
4/21/2024
Next Earnings (Confirmed)
4/30/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Testing laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:NEO
Employees
2,100
Year Founded
2002

Price Target and Rating

Average Stock Price Target
$19.50
High Stock Price Target
$24.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+44.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

Net Income
$-87,970,000.00
Pretax Margin
-16.41%

Debt

Sales & Book Value

Annual Sales
$591.64 million
Cash Flow
$0.28 per share
Book Value
$7.39 per share

Miscellaneous

Free Float
126,006,000
Market Cap
$1.73 billion
Optionable
Optionable
Beta
1.10

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Christopher Michael Smith BSc (Age 61)
    CEO & Director
    Comp: $3.52M
  • Mr. Jeffrey S. Sherman M.B.A. (Age 58)
    Chief Financial Officer
    Comp: $492.31k
  • Mr. Warren Stone (Age 51)
    President of Clinical Division
    Comp: $722.79k
  • Mr. Vishal Sikri (Age 47)
    President of Pharma Services, President & Chief Commercial Officer Inivata
    Comp: $1.21M
  • Gregory D. Aunan
    Senior VP & Chief Accounting Officer
  • Ms. Kendra Sweeney
    Vice President of Investor Relations & Communications
  • Ms. Alicia Olivo (Age 40)
    General Counsel & Corporate Secretary
  • Mr. Hutan Hashemi J.D. (Age 45)
    Chief Compliance Officer
  • Dr. Derek Lyle M.D.
    Chief Medical Officer
  • Ms. Melody Harris Esq. (Age 58)
    J.D., President of Enterprise Operations

NEO Stock Analysis - Frequently Asked Questions

Should I buy or sell NeoGenomics stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NEO shares.
View NEO analyst ratings
or view top-rated stocks.

What is NeoGenomics' stock price target for 2024?

10 Wall Street analysts have issued 1 year price targets for NeoGenomics' stock. Their NEO share price targets range from $17.00 to $24.00. On average, they anticipate the company's share price to reach $19.50 in the next twelve months. This suggests a possible upside of 44.1% from the stock's current price.
View analysts price targets for NEO
or view top-rated stocks among Wall Street analysts.

How have NEO shares performed in 2024?

NeoGenomics' stock was trading at $16.18 at the start of the year. Since then, NEO shares have decreased by 16.4% and is now trading at $13.53.
View the best growth stocks for 2024 here
.

When is NeoGenomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024.
View our NEO earnings forecast
.

How can I listen to NeoGenomics' earnings call?

NeoGenomics will be holding an earnings conference call on Tuesday, April 30th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) announced its quarterly earnings results on Tuesday, February, 20th. The medical research company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.05. The medical research company had revenue of $155.55 million for the quarter, compared to the consensus estimate of $152.90 million. NeoGenomics had a negative trailing twelve-month return on equity of 4.13% and a negative net margin of 14.87%.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics updated its first quarter 2024 earnings guidance on Wednesday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $148.0 million-$151.0 million, compared to the consensus revenue estimate of $149.4 million.

What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?

116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by many different institutional and retail investors. Top institutional investors include Silverberg Bernstein Capital Management LLC (0.02%), Allspring Global Investments Holdings LLC (0.02%) and Banque Cantonale Vaudoise (0.01%). Insiders that own company stock include Alicia C Olivo, Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Kathryn B Mckenzie, Mark Mallon, Robert J Shovlin and William Bonello.
View institutional ownership trends
.

How do I buy shares of NeoGenomics?

Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does NeoGenomics have any subsidiaries?
The following companies are subsidiares of NeoGenomics: Clarient Inc., Clarient Diagnostic Services Inc, Clarient Inc, Cynogen Inc., GE Medical Holding AB., Genesis Acquisition Holding Corp, Genesis Acquisition Holdings Corp., Genoptix, Genoptix Inc., Inivata Inc., Inivata Limited, Inivata Limited., Minuet Diagnostics Inc., NeoGenomics Bioinformatics Inc., NeoGenomics Europe SA, NeoGenomics Foundation Inc, NeoGenomics Laboratories Inc, NeoGenomics Singapore Pte. Ltd, Path Labs LLC, Suzhou NeoGenomics Pharmaceutical Research Co. Limited, Trapelo Health, and Trapelo Health LLC.
Read More
This page (NASDAQ:NEO) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners